MarketScreener Homepage > Equities > Nyse > Edwards Lifesciences Corporation EW

Report

Delayed Nyse - 01/25 04:10:00 pm
85.89	USD		+0.43%

01/13

EDWARDS LIFESCIENCES : To Host Earnings Conference Call On January 27, 2021

2020

EDWARDS LIFESCIENCES : Treats First Patient in Study Evaluating Device for Mitral Valve Repair Surgery

2020

EDWARDS LIFESCIENCES : Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease

Summary

Quotes 5-day view Delayed Quote.

Delayed Nyse

01/19/2021	01/20/2021	01/21/2021	01/22/2021	01/25/2021	Date
87.91(c)	88.1(c)	87.23(c)	85.52(c)	85.89(c)	Last
1 976 894	3 561 984	1 796 317	3 278 941	3 297 685	Volume
+0.05%	+0.22%	-0.99%	-1.96%	+0.43%	Change

More quotes

Financials (USD)

Sales 2020	4 385 M - -
Net income 2020	819 M - -
Net cash position 2020	815 M - -
P/E ratio 2020	64,9x
Yield 2020	-

Sales 2021	5 098 M - -
Net income 2021	1 249 M - -
Net cash position 2021	1 588 M - -
P/E ratio 2021	42,6x
Yield 2021	-

Capitalization	53 531 M 53 531 M -
EV / Sales 2020	12,0x
EV / Sales 2021	10,2x
Nbr of Employees	13 900
Free-Float	97,4%

More Financials

Company

Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - hemodynamic monitoring systems (61.4%); - heart valves and surgery products (20.4%); - other (18.1%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the...

Sector

Advanced Medical Equipment & Technology

Calendar

01/27

Earnings Release

More about the company

Notations Surperformance© of Edwards Lifesciences Corporation

Trading Rating :

Investor Rating :

More Ratings

All news about EDWARDS LIFESCIENCES CORPORATION

01/13	EDWARDS LIFESCIENCES : To Host Earnings Conference Call On January 27, 2021	PR
2020	EDWARDS LIFESCIENCES : Treats First Patient in Study Evaluating Device for Mitra..	MT
2020	EDWARDS LIFESCIENCES : Treats First Patient In U.S. Clinical Trial Evaluating Mi..	PR
2020	EDWARDS LIFESCIENCES' : SAPIEN 3 Valves Gets Expanded Use Approval In Canada	MT
2020	EDWARDS LIFESCIENCES : SAPIEN 3 TAVI Receives Expanded Approval In Canada	AQ
2020	EDWARDS LIFESCIENCES : Citigroup Downgrades Edwards Lifesciences to Neutral From..	MT
2020	EDWARDS LIFESCIENCES : Goldman Sachs Adjusts Edwards Lifesciences PT to $94 From..	MT
2020	EDWARDS LIFESCIENCES : Morgan Stanley Adjusts Price Target on Edwards Lifescienc..	MT
2020	EDWARDS LIFESCIENCES : Stifel Nicolaus Adjusts Price Target for Edwards Lifescie..	MT
2020	EDWARDS LIFESCIENCES : Oppenheimer Adjusts Edwards Lifesciences PT to $94 From $..	MT
2020	EDWARDS LIFESCIENCES : SVB Leerink Adjusts Price Target on Edwards Lifesciences ..	MT
2020	EDWARDS LIFESCIENCES : Piper Sandler Adjusts Price Target on Edwards Lifescience..	MT
2020	EDWARDS LIFESCIENCES : Raymond James Adjusts Edwards Lifesciences' Price Target ..	MT
2020	EDWARDS LIFESCIENCES : Canaccord Genuity Adjusts Price Target on Edwards Lifesci..	MT
2020	EDWARDS LIFESCIENCES : UBS Adjusts Price Target on Edwards Lifesciences to $90 F..	MT

More news

News in other languages on EDWARDS LIFESCIENCES CORPORATION

01/22	EDWARDS LIFESCIENCES CORPORATION : publication des résultats annuels
01/22	EDWARDS LIFESCIENCES CORPORATION : Veröffentlichung des Jahresergebnisses
2020	EDWARDS LIFESCIENCES CORPORATION : publication des résultats trimestriels
2020	EDWARDS LIFESCIENCES CORPORATION : Veröffentlichung des Quartalsergebnisses
2020	EDWARDS LIFESCIENCES CORPORATION : publication des résultats semestriels

More news

Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION

2020	EDWARDS LIFESCIENCES : Citigroup Downgrades Edwards Lifesciences to Neutral From..	MT
2020	EDWARDS LIFESCIENCES : Goldman Sachs Adjusts Edwards Lifesciences PT to $94 From..	MT
2020	EDWARDS LIFESCIENCES : Morgan Stanley Adjusts Price Target on Edwards Lifescienc..	MT

More recommendations

Provided by Scoopnest.com

Chart EDWARDS LIFESCIENCES CORPORATION

Duration : Period :

Edwards Lifesciences Corporation Technical Analysis Chart | EW | US28176E1082 | MarketScreener

Full-screen chart

Technical analysis trends EDWARDS LIFESCIENCES CORPORATION

	Short Term	Mid-Term	Long Term
Trends	Neutral	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	26
Average target price	93,43 $
Last Close Price	85,89 $
Spread / Highest target	29,2%
Spread / Average Target	8,78%
Spread / Lowest Target	-25,5%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Michael A. Mussallem	Chairman & Chief Executive Officer
Scott B. Ullem	Chief Financial Officer & Vice President
John P. McGrath	Vice President-Quality, Regulatory & Clinical
Todd J. Brinton	Chief Scientific Officer & VP-Advanced Technology
William J. Link	Independent Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

EDWARDS LIFESCIENCES CORPORATION	-5.85%	53 531



THERMO FISHER SCIENTIFIC	10.48%	205 631
DANAHER CORPORATION	7.21%	169 176
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	14.55%	91 552
INTUITIVE SURGICAL, INC.	-8.08%	88 403
ILLUMINA, INC.	13.78%	61 466

More Results